February 23, 2009

Statement by Sophie Delaunay Executive Director, MSF-USA

This annual Ministerial review focusing on philanthropy and the Global Health Agenda clearly shows recognition of the urgency to address global health challenges. However, this initiative cannot replace the critical need for greater government leadership to stimulate medical innovation for neglected diseases affecting millions in the poorest corners of the world.

July 29, 2008

MSF official statement

Once again in this type of situation, there is a lot of confusion introduced, whether deliberately or through a lack of correct information, between the role of the states that have ratified the statute of the International Criminal Court (ICC), the United Nations, and the activities of independent humanitarian organizations such as Doctors Without Borders/Médecins Sans Frontières (MSF).

May 22, 2008

Before the High Level task force communicates its first Comprehensive Framework for Action, Médecins Sans Frontières urges careful consideration of the population that is most vulnerable to the dire consequences of malnutrition – children under two.

April 30, 2008

My name is Dr. Tido von Schoen-Angerer and I am speaking on behalf of Médecins Sans Frontières. Thank you for the opportunity to address this important gathering.

In 2000, I was working in one of MSF’s AIDS projects. Our response to the pandemic was one based on a simple medical decision: faced with the urgency of patients dying, the only acceptable response was to treat. This was an ethical imperative, to treat, regardless of the difficulties.

March 15, 2007

U.S congressional briefing delivered by Dr. Buddhima Lokuge, U.S. Manager of MSF's Campaign for Access to Essential Medicines on Thailand's compulsory drug licensing.

February 21, 2007

Presentation by Fabrice Weissman, MSF Foundation and former Head of Mission for MSF in Darfur, Sudan to Panel Discussion at Columbia University School of International and Public Affairs

April 27, 2006

Dear Mr. White, We are writing to you to express our concern about the lack of availability in developing countries of the new melt extrusion (Meltrex) formulation of lopinavir/ritonavir (LPV/r), marketed as Kaletra (200/50mg tablets).

January 23, 2006

A Statement Delivered by Helen O'Neill, Deputy Director of Operations, Médecins Sans Frontières (MSF) at the United Nations Security Council "Arria Formula" meeting

July 26, 2005

Statement by Dr. Nathalie Civet, Head of Mission in Sudan for Médecins sans Frontières (MSF) delivered to the United Nations Security Council "Arria Formula" meeting

July 13, 2005

Presentation of Nicolas de Torrente, Executive Director, MSF-USA, on Lessons Learned From the Recent Indian Ocean Earthquake/Tsunami – Response Challenges.